Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | TOP2A | P11388 | 1/20 | 0.41 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 2/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15192035 | 1.00 | RAB9A (0.61) | RAB9AKDM4ENPC1SMN1; SMN2TOP2A | |
| SCHEMBL15198025 | 0.94 | RAB9A (0.71) | RAB9AKDM4ENPC1SMN1; SMN2TOP2A | |
| SCHEMBL8414209 | 0.94 | RAB9A (0.71) | RAB9AKDM4ENPC1SMN1; SMN2TOP2A | |
| SCHEMBL9212764 | 0.89 | RAB9A (0.58) | RAB9AKDM4ENPC1SMN1; SMN2RNASE1 | |
| SCHEMBL7159755 | 0.89 | RAB9A (0.58) | RAB9AKDM4ENPC1SMN1; SMN2RNASE1 | |
| SCHEMBL9216936 | 0.89 | RAB9A (0.58) | RAB9AKDM4ENPC1SMN1; SMN2RNASE1 | |
| SCHEMBL13614207 | 0.85 | RAB9A (0.68) | RAB9AKDM4ENPC1SMN1; SMN2RNASE1 | |
| SCHEMBL4294461 | 0.85 | RAB9A (0.68) | RAB9AKDM4ENPC1SMN1; SMN2RNASE1 | |
| SCHEMBL14953175 | 0.85 | RAB9A (0.68) | RAB9AKDM4ENPC1SMN1; SMN2TOP2A | |
| SCHEMBL16072774 | 0.84 | RAB9A (0.41) | RAB9AKDM4ENPC1SMN1; SMN2TOP2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3781544-B1 | PROCESS FOR THE PREPARATION OF ILOPROST | EUROAPI HUNGARY LLC (HU) | 2023-11-08 | — | — | EP | disclosed |
| US-11535580-B2 | Process for the preparation of iloprost | CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. (HU) | 2022-12-27 | — | — | US | disclosed |
| US-20210147329-A1 | PROCESS FOR THE PREPARATION OF ILOPROST | CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. (HU) | 2021-05-20 | — | — | US | disclosed |
| WO-2019202345-A2 | PROCESS FOR THE PREPARATION OF ILOPROST | CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. (HU) | 2019-10-24 | — | — | WO | disclosed |
| US-4532236-A | Certain prostacyclins and their blood-pressure-lowering and thrombocyte-aggregation-inhibiting compositions and methods | SCHERING AKTIENGESELLSCHAFT (DE) | 1985-07-30 | — | — | US | disclosed |
| US-4378370-A | Certain 5-cyano-16-fluoro-prostacyclins and their use as pharmaceuticals | SCHERING AKTIENGESELLSCHAFT (DE) | 1983-03-29 | — | — | US | disclosed |
| US-4359581-A | Process for the production of caracyclin intermediates | SCHERING AG (DE) | 1982-11-16 | — | — | US | disclosed |
| EP-0058632-A1 | (13E)-(8R,11R,12R)-11,15-dihydroxy-16,19-dimethyl-9-oxo-13,18-prostadienoic acids and their salts, their preparation and pharmaceutical compositions | SCHERING AKTIENGESELLSCHAFT (DE) | 1982-08-25 | — | — | EP | disclosed |
| EP-0051597-A1 | NEW PROSTACYCLIN DERIVATIVES AND THEIR PREPARATION AND UTILIZATION THEREOF. | SCHERING AG (DE) | 1982-05-19 | — | — | EP | disclosed |
| EP-0041661-A2 | Preparation of intermediates of carbaprostacyclines | SCHERING AKTIENGESELLSCHAFT (DE) | 1981-12-16 | — | — | EP | disclosed |
| WO-1981002296-A1 | NEW PROSTA ERIVATIVES,PREPARATION AND UTILIZATION THEREOF | SCHERING AG (DE) | 1981-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147329-A1 | PROCESS FOR THE PREPARATION OF ILOPROST | PTGIS, PTGER1, PTGIR | RAB9A 2847/4885KDM4E 4668/4885NPC1 2183/4885 |
| US-11535580-B2 | Process for the preparation of iloprost | PTGIS, PTGER1, PTGIR | RAB9A 2847/4885KDM4E 4668/4885NPC1 2183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.